Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-297

So it is OK to ignore other significant parts of the pharmaceutical industry for comparisons sake in terms of violations?

For example from https://violationtracker.goodjobsfirst.org/parent-totals

This is where we start to see other multinational pharmaceutical businesses, down to and including Novartis. Not the best in a manner of speaking, but this is a better view point. One way of looking at this could be Novartis has incurred $2B less in fines than the leader of the pack, with half the number of violations as recorded.

Pfizer, where have I heard that name recently...... I did mention Johnson and Johnson a little earlier too. Oooh and looky there, Teva, well at least we did 3 or so better than last time